期刊
SEMINARS IN CANCER BIOLOGY
卷 51, 期 -, 页码 36-49出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2017.12.004
关键词
Biomarkers; Detection; DNA methylation; Gastrointestinal cancers; Prognosis
类别
资金
- South-Eastern Norway Regional Health Authority
- Research Council of Norway [239961]
- Centre of Excellence funding scheme [179571]
- National Cancer Institute, National Institute of Health [CA72851, CA181572, CA184792, CA187956, CA202797]
- Cancer Prevention Research Institute of Texas [RP140784]
- Sammons Cancer Center
- Baylor Foundation
- Baylor Scott & White Research Institute, Dallas, TX, USA
Each year, almost 4.1 million people are diagnosed with gastrointestinal (GI) cancers. Due to late detection of this disease, the mortality is high, causing approximately 3 million cancer-related deaths annually, worldwide. Although the incidence and survival differs according to organ site, earlier detection and improved prognostication have the potential to reduce overall mortality burden from these cancers. Epigenetic changes, including aberrant promoter DNA methylation, are common events in both cancer initiation and progression. Furthermore, such changes may be identified non-invasively with the use of PCR based methods, in bodily fluids of cancer patients. These features make aberrant DNA methylation a promising substrate for the development of disease biomarkers for early detection, prognosis and for predicting response to therapy. In this article, we will provide an update and current clinical perspectives for DNA methylation alterations in patients with colorectal, gastric, pancreatic, liver and esophageal cancers, and discuss their potential role as cancer biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据